Sodium-Glucose Cotransporter-2 Inhibitors and Arrhythmias
SGLT2i therapy was associated with an overall lower risk of atrial arrythmia and SCD in patients with type 2 diabetes mellitus and/or HF or chronic kidney disease. However, SGLT2i therapy was not associated with a lower risk of ventricular arrhythmia.
Authors
- Akash Jaiswal (ORCID: https://orcid.org/0000-0002-5980-2361)
- Erin D. Michos (ORCID: https://orcid.org/0000-0002-5547-5084)
- Danisha Kumar
- Emelia J. Benjamin (ORCID: https://orcid.org/0000-0003-4076-2336)
- Gregg C. Fonarow (ORCID: https://orcid.org/0000-0002-3192-8093)
- Yusra Nasir
- Novonil Deb (ORCID: https://orcid.org/0000-0002-9005-8358)
- Song Peng Ang (ORCID: https://orcid.org/0000-0001-8557-9880)
- Amey Joshi (ORCID: https://orcid.org/0000-0002-5524-9124)
- Dhrubajyoti Bandyopadhyay (ORCID: https://orcid.org/0000-0002-0709-4324)
- Vikash Jaiswal (ORCID: https://orcid.org/0000-0002-2021-1660)
Institutions
- Rutgers, The State University of New Jersey (US)
- Boston University (US)
- Boston Medical Center (US)
- Harvard University (US)
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- Sparrow Hospital (US)
- Ronald Reagan UCLA Medical Center (US)
- Community Medical Center (US)
- Larkin Community Hospital (US)
- Dow University of Health Sciences (PK)
- North Bengal Medical College and Hospital (IN)
- Massachusetts General Hospital (US)
- University of Oklahoma Health Sciences Center (US)
- All India Institute of Medical Sciences (IN)
Publication Details
- Journal
- JACC Advances
- Published
- 2025-02-22
- DOI
- https://doi.org/10.1016/j.jacadv.2025.101615
- Citations
- 18
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 23.31